We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Consensus is building around apolipoprotein B (apoB) as the preferred tool for gauging the effectiveness of LDL-lowering therapies. Is it accurate, reproducible and cost-effective? Host Dr. Larry Kaskel welcomes Dr. Allan Sniderman, professor of cardiology at the McGill University Health Centre in Montreal, for a noteworthy discussion about apoB and its impact on our approach to atherogenic risk management. Will this test soon become standard in a lipid panel?
Brought to you by:
Consensus is building around apolipoprotein B (apoB) as the preferred tool for gauging the effectiveness of LDL-lowering therapies. Is it accurate, reproducible and cost-effective? Host Dr. Larry Kaskel welcomes Dr. Allan Sniderman, professor of cardiology at the McGill University Health Centre in Montreal, for a noteworthy discussion about apoB and its impact on our approach to atherogenic risk management. Will this test soon become standard in a lipid panel?
Brought to you by:
Stay current with the best on medical education
